News Release

Santen Files for Manufacturing and Marketing Approval for its Glaucoma and Ocular Hypertension Drug Candidate DE-085 (INN: Tafluprost)

August 1, 2006 Osaka Japan -- Santen Pharmaceutical Co., Ltd. announced that it had applied manufacturing and marketing approval for its glaucoma and ocular hypertension treatment DE-085 (INN: Tafluprost) to the Japanese Ministry of Health, Labour and Welfare on July 31,2006.

DE-085 is a novel prostaglandin drug candidate being studied for the reduction of intraocular pressure in primary open angle glaucoma and ocular hypertension which is under co-development by Santen and Asahi Glass Co., Ltd., Tokyo. Santen is conducting pharmaceutical and clinical development, while Asahi Glass is responsible for manufacturing development of the active pharmaceutical ingredient.
Glaucomatous damage to the optic nerve causes a defect of the visual field. One of the factors leading to the optic nerve disorder is elevation of intraocular pressure caused by aqueous humor outflow resistance. DE-085 demonstrated a potent and stable inter ocular pressure lowering effect by promoting uveoscleral outflow. No serious side effect to the eye or entire body has been observed.

Causing the major visual disturbance such as blindness and visual loss, and speculating that there are many untreated patients, early detection and early treatment of glaucoma is becoming an important issue. Santen expects DE-085 will offer a new treatment option for glaucoma and patients, leading to their improved quality of life.

About DE-085

Development code:	DE-085
Generic name:	Tafluprost
Dosage form:	Water-based ophthalmic solution
Indication:	Glaucoma and ocular hypertension
Dosage:	1 drop/time, once daily
Preservation method	Can be stored at room temperature

###